MX2024013807A - Soluciones acuosas de ticagrelor, metodo de fabricacion y usos - Google Patents

Soluciones acuosas de ticagrelor, metodo de fabricacion y usos

Info

Publication number
MX2024013807A
MX2024013807A MX2024013807A MX2024013807A MX2024013807A MX 2024013807 A MX2024013807 A MX 2024013807A MX 2024013807 A MX2024013807 A MX 2024013807A MX 2024013807 A MX2024013807 A MX 2024013807A MX 2024013807 A MX2024013807 A MX 2024013807A
Authority
MX
Mexico
Prior art keywords
ticagrelor
aqueous
solutions
manufacturing
intravenous administration
Prior art date
Application number
MX2024013807A
Other languages
English (en)
Spanish (es)
Inventor
Atul Patil
Original Assignee
Hyloris Dev Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2022/063185 external-priority patent/WO2023222184A1/en
Application filed by Hyloris Dev Sa filed Critical Hyloris Dev Sa
Publication of MX2024013807A publication Critical patent/MX2024013807A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2024013807A 2022-05-16 2024-11-07 Soluciones acuosas de ticagrelor, metodo de fabricacion y usos MX2024013807A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2022/063185 WO2023222184A1 (en) 2022-05-16 2022-05-16 Aqueous ticagrelor solution, method of manufacturing and uses
EP2023055736 2023-03-07
PCT/EP2023/063071 WO2023222660A1 (en) 2022-05-16 2023-05-16 Aqueous ticagrelor solutions, method of manufacturing and uses

Publications (1)

Publication Number Publication Date
MX2024013807A true MX2024013807A (es) 2025-02-10

Family

ID=86604209

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024013807A MX2024013807A (es) 2022-05-16 2024-11-07 Soluciones acuosas de ticagrelor, metodo de fabricacion y usos

Country Status (9)

Country Link
US (1) US20250235455A1 (cg-RX-API-DMAC10.html)
EP (1) EP4525931A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025515559A (cg-RX-API-DMAC10.html)
KR (1) KR20250024925A (cg-RX-API-DMAC10.html)
CN (1) CN119212736A (cg-RX-API-DMAC10.html)
AU (1) AU2023271339A1 (cg-RX-API-DMAC10.html)
CA (1) CA3252689A1 (cg-RX-API-DMAC10.html)
MX (1) MX2024013807A (cg-RX-API-DMAC10.html)
WO (1) WO2023222660A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260113060A (ko) * 2023-11-16 2026-07-21 하이로리스 디벨롭먼츠 에스에이 피부경유 관상동맥 중재술 (pci)을 겪은 환자에서 허혈성 사건의 치료, 감소 또는 예방에 사용을 위한 티카그렐러 iv
WO2025104274A1 (en) * 2023-11-16 2025-05-22 Hyloris Developments Sa Ticagrelor iv for use in the prevention of thromboembolic events
AU2024386725A1 (en) * 2023-11-22 2026-04-30 Hyloris Developments Sa Intravenous administration of ticagrelor compositions in a patient who was previously administered an opioid in order to treat coagulation and avoid reduced ticagrelor uptake
CN117919246A (zh) * 2024-01-26 2024-04-26 重庆东得医药科技有限公司 一种以左西孟旦为活性成分的组合物及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3100728T3 (pl) * 2009-05-13 2020-05-18 Cydex Pharmaceuticals, Inc. Kompozycje farmaceutyczne zawierające prasugrel i pochodne cyklodekstryny oraz sposoby ich wytwarzania i zastosowania
CN110917167A (zh) * 2018-09-19 2020-03-27 河南天晟泰丰医药科技有限公司 替格瑞洛肠溶缓释软胶囊及其制备方法
WO2021096444A1 (en) * 2019-11-13 2021-05-20 Santa Farma İlaç Sanayi̇ A.Ş. Pharmaceutical compositions comprising ticagrelor

Also Published As

Publication number Publication date
CN119212736A (zh) 2024-12-27
US20250235455A1 (en) 2025-07-24
EP4525931A1 (en) 2025-03-26
JP2025515559A (ja) 2025-05-20
WO2023222660A1 (en) 2023-11-23
CA3252689A1 (en) 2023-11-23
KR20250024925A (ko) 2025-02-20
AU2023271339A1 (en) 2024-10-17

Similar Documents

Publication Publication Date Title
US9597398B2 (en) Formulations of bendamustine
MX2023005763A (es) Composiciones y metodos para la administracion dermica profunda de farmacos.
US20230414617A1 (en) Pharmaceutical composition comprising acid-base neutralization combination and application thereof
JP2013181020A (ja) 眼科用組成物
EP2421522A1 (de) Paracetamol zur parenteralen verabreichung
JP2011246383A (ja) コンタクトレンズ装用者用疲れ目改善用眼科製剤
JOP20250146A1 (ar) صيغ ليدوكايين منظمة قابلة للحقن وطرق تصنيعها
TWI712429B (zh) 水性醫藥組成物
CA3214630A1 (en) Pharmaceutical composition comprising the compound smtp-7
RU2576612C2 (ru) Трансдермальный абсорбируемый препарат
EP3328357B1 (de) Konzentrat enthaltend alprostadil
JP2009161456A (ja) 眼科用組成物
ATE386512T1 (de) Vorgemischte amiodaron-haltige parenterale lösung und deren herstellungsverfahren
JP5993620B2 (ja) 点眼剤
DE102007014947B4 (de) Stabilisierte wässrige Lösungen von Ergolinverbindungen
US20170340647A1 (en) Preservative-free Treprostinil Formulations and Methods and Devices for Use with Same
MY202996A (en) Ophthalmic composition for treatment of cornea wounds associated wth diabetes mellitus
EP3328356A1 (de) Konzentrat enthaltend alprostadil
IL312623A (en) Preserved formulations
US20230241218A1 (en) Formulations of bendamustine
CN104257607A (zh) 一种紫杉醇注射液及其制备方法
RU2013142835A (ru) Способ лечения ишемического инсульта
JPH06256212A (ja) オーレオバシジン類のリポソーム製剤